Abstract
Cardiac diseases are the major causes of morbidity and mortality in the world. Cardiomyocyte death is a common consequence of many types of heart diseases and is usually irreversible. Scar tissues formed by cardiac fibroblasts serve compensatory roles for the injured heart but eventually weaken cardiac function and result in life-threatening heart failures. Unfortunately, adult human hearts have limited regenerative capacities. In the past decades, many interventional approaches have been taken in an attempt to restore functional cardiomyocytes in an injured heart. Promising advances have been made in directly reprogramming mouse fibroblasts into cardiomyocyte-like cells both in vitro and in vivo. Recently, several different methods have been reported, including the use of transcription factors and microRNAs. In addition, two in vivo studies showed heart function improvements with delivery of reprogramming factors in mouse infarcted hearts. Although many of these studies are at early preliminary stages, the plausibility of applying cardiac reprogramming on patients for regenerative purposes is exciting, and may lead to numerous novel research directions in the field. This review will discuss the history, recent advances and challenges of cellular reprogramming, specifically in the field of cardiac regeneration.
Keywords: Cellular reprogramming, cardiac regeneration, iPS, iCM, myocardial infarction, fibroblasts, cardiomyocytes, cardiac disease
Current Gene Therapy
Title:Direct Somatic Cell Reprogramming: Treatment of Cardiac Diseases
Volume: 13 Issue: 2
Author(s): Chuner Guo, Kishan Patel and Li Qian
Affiliation:
Keywords: Cellular reprogramming, cardiac regeneration, iPS, iCM, myocardial infarction, fibroblasts, cardiomyocytes, cardiac disease
Abstract: Cardiac diseases are the major causes of morbidity and mortality in the world. Cardiomyocyte death is a common consequence of many types of heart diseases and is usually irreversible. Scar tissues formed by cardiac fibroblasts serve compensatory roles for the injured heart but eventually weaken cardiac function and result in life-threatening heart failures. Unfortunately, adult human hearts have limited regenerative capacities. In the past decades, many interventional approaches have been taken in an attempt to restore functional cardiomyocytes in an injured heart. Promising advances have been made in directly reprogramming mouse fibroblasts into cardiomyocyte-like cells both in vitro and in vivo. Recently, several different methods have been reported, including the use of transcription factors and microRNAs. In addition, two in vivo studies showed heart function improvements with delivery of reprogramming factors in mouse infarcted hearts. Although many of these studies are at early preliminary stages, the plausibility of applying cardiac reprogramming on patients for regenerative purposes is exciting, and may lead to numerous novel research directions in the field. This review will discuss the history, recent advances and challenges of cellular reprogramming, specifically in the field of cardiac regeneration.
Export Options
About this article
Cite this article as:
Guo Chuner, Patel Kishan and Qian Li, Direct Somatic Cell Reprogramming: Treatment of Cardiac Diseases, Current Gene Therapy 2013; 13 (2) . https://dx.doi.org/10.2174/1566523211313020007
DOI https://dx.doi.org/10.2174/1566523211313020007 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dyslipidemia, Vascular Atheroma and Statins
Current Vascular Pharmacology The Cost-Effectiveness of Palivizumab in the Prevention of Respiratory Syncytial Virus Bronchiolitis: A Systematic Review
Current Respiratory Medicine Reviews Amelioration of Myocardial Ischemic Reperfusion Injury with Calendula Officinalis
Current Pharmaceutical Biotechnology Gesture Interaction for Coronary Heart Diseases Based on Wavelet Transform and Semi-Continuous Hidden Markov Model in Augmented Reality
Recent Advances in Electrical & Electronic Engineering Honey, Health and Longevity
Current Aging Science Role of ARBs in the Blood Hypertension Therapy and Prevention of Cardiovascular Events
Current Drug Targets Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia
Current Pharmaceutical Design Therapeutic Indications and Action Mechanisms of Bilirubin: Suggestions from Natural Calculus Bovis
Current Signal Transduction Therapy Editorial [Bioengineering and Clinical Perspectives in Diagnostic and Therapeutic Applications of Microbubbles (Executive Guest Editor: Theodore G. Papaioannou)]
Current Pharmaceutical Design Use of Plant Sterol and Stanol Fortified Foods in Clinical Practice
Current Medicinal Chemistry Targeting Lung Inflammation: Novel Therapies for the Treatment of COPD
Current Respiratory Medicine Reviews Marine n-3 Fatty Acids for Cardiovascular Risk Reduction and Disease Control in Rheumatoid Arthritis: “Kill Two Birds with One Stone”?
Current Pharmaceutical Design Colesevelam: A New and Improved Bile Acid Sequestrant?
Current Pharmaceutical Design An Overview of Published Papers and Important Developments in the Past Three Years
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Angiotensin II Receptor Blocker as an Inverse Agonist: A Current Perspective
Current Hypertension Reviews A Single Pill to Treat Postmenopausal Hypertension? Not Yet
Current Topics in Medicinal Chemistry Heat Shock Protein-60 and Risk for Cardiovascular Disease
Current Pharmaceutical Design Pharmacogenetics of Antithrombotic Drugs
Current Pharmaceutical Design Cardiovascular Drug Development Using Radiopharmaceuticals
Current Pharmaceutical Design Beta-Blockers in the Management of Coronary Artery Disease: Are we on the Verge of a New Paradigm Shift?
Recent Patents on Cardiovascular Drug Discovery